NMP in myeloma
NMP in myeloma
NMP在骨髓瘤中的应用
批准号：
nhmrc : GNT1067516
负责人：
A/Pr Jake Shortt
金额：
$53.36万
依托单位国家：
澳大利亚
项目类别：
Project Grants
财政年份：
2014
资助国家：
澳大利亚
项目状态：
已结题
起止时间：
2014-01-01 至 --
中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
We have newly discovered that a simple molecule called NMP has the ability to control myeloma cells that have become resistant to other available treatments. NMP works by enhancing immune function and by killing myeloma cells directly by inhibiting survival signals. NMP is different from all other types of available myeloma treatments. We intend to test the safety and power of NMP in the treatment of myeloma by running a clinical trial of NMP in patients with relapsed myeloma.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Exploiting and defining the immune regulatory activities of BET bromodomain inhibitors
-
批准号：nhmrc : 1123432
-
项目类别：Project Grants
-
资助金额：$61.56万
-
财政年份：2017
-
负责人：A/Pr Jake Shortt
-
依托单位：
Molecular & Translational Characterisation of IMiD-Mediated BET-Protein Degradation in Multiple Myeloma
-
批准号：nhmrc : GNT1127387
-
项目类别：Project Grants
-
资助金额：$49.79万
-
财政年份：2017
-
负责人：A/Pr Jake Shortt
-
依托单位：
Molecular & Translational Characterisation of IMiD-Mediated BET-Protein Degradation in Multiple Myeloma
-
批准号：nhmrc : 1127387
-
项目类别：Project Grants
-
资助金额：$33.97万
-
财政年份：2017
-
负责人：A/Pr Jake Shortt
-
依托单位：
A phase I study of the first in class dual IMiD/bromodomain inhibitor N-methyl-2-pyrrolidone (NMP) in relapsed and refractory multiple myeloma.
-
批准号：nhmrc : 1067516
-
项目类别：Project Grants
-
资助金额：$36.74万
-
财政年份：2014
-
负责人：A/Pr Jake Shortt
-
依托单位：
国内基金
海外基金
间充质干细胞在多发性骨髓瘤耐药中的作用研究
-
批准号：30872997
-
项目类别：面上项目
-
资助金额：28.0万元
-
批准年份：2008
-
负责人：王晓芳
-
依托单位：
